Navigation Links
Lilly Announces 2014 Financial Guidance, Reconfirms 2013 Expectations
Date:1/7/2014

INDIANAPOLIS, Jan. 7, 2014 /PRNewswire/ --

  • 2014 revenue anticipated to be between $19.2 billion and $19.8 billion.
  • Earnings per share for 2014 are expected to be in the range of $2.77 - $2.85, reflecting the impact of patent expirations.
  • 2014 net income and operating cash flow goals of $3.0 billion and $4.0 billion, respectively, are expected to be achieved.
  • Company reaffirms commitment to maintain dividend at least at current level.
  • Late-stage pipeline includes 13 potential new medicines in either Phase III development or submission stage.
  • Company's 2013 financial expectations remain unchanged.

Eli Lilly and Company (NYSE: LLY) today announced its financial guidance for 2014, highlighted key events for the upcoming year and reiterated its strategy to return to growth beginning in 2015. The company also indicated that its 2013 financial expectations remain unchanged. Fourth quarter and full-year 2013 financial results will be announced on January 30, 2014.

"We continue to focus on the three strategic priorities that have guided our efforts throughout an extended period of patent expirations," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "First and foremost, we are replenishing and advancing our pipeline. Today, we have 13 potential new medicines in Phase III testing or submission stage, with 26 more in Phase II.  We anticipate obtaining regulatory approvals for and successfully launching multiple products each year for the next few years. At the same time, we aim to sustain strong performance for our currently marketed brands and key growth areas. Finally, we continue to drive productivity gains across our business in
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lilly Sets Dates and Conference Calls for 2014 Financial Guidance and Fourth-Quarter 2013 Financial Results Announcements
2. Lilly to Present at J.P. Morgan Healthcare Conference
3. Lilly Declares First-Quarter 2014 Dividend
4. Increased Dividends, Clinical Trial Results, Survey Results, and Updated Financial Guidance - Research Report on Aetna, Biogen, Eli Lilly, WellPoint, and Laboratory Corp. of America
5. Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder
6. Zacks Industry Outlook Highlights: Merck, Pfizer, Forest Laboratories, Sanofi and Eli Lilly
7. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
8. Surveyed Endocrinologists Consider Eli Lillys Dulaglutide To Have an Edge Over Competitors for the Treatment of Type 2 Diabetes Patients Who Are Inadequately Controlled On Metformin
9. Lilly Statement on Contribution to Indiana Biosciences Research Institute
10. Lilly Announces Significant Global Insulin Manufacturing Capacity Investments in Response to Growing Diabetes Epidemic
11. Medtronic, Lilly Diabetes Join Together as First Ever National Presenting Sponsors of the JDRF Walk To Cure Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... , Oct. 22, 2014  Recently published clinical studies ... the already substantial database of evidence. This data has ... Stretta therapy for sufferers of refractory GERD. ... evidence supporting Stretta therapy as a safe and ... make Stretta therapy available to nearly 50 million Americans. ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2
... , , , ... CXM ) today announced that all patients enrolled in ... evaluation period and that it plans to provide detailed safety and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ) , , The Phase ...
... , , , RIDGEFIELD, ... (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran)(1) ... (ESC) Congress in Barcelona on Sunday, Aug. 30. The ... efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, ...
Cached Medicine Technology:Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 8Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... Salamon HealthDay Reporter , TUESDAY, ... vitro fertilization (IVF) are only about half as likely as ... technique, new research indicates, and the racial disparity persists even ... 31 percent of white patients became pregnant after IVF, compared ... than 4,000 IVF cycles over two years to tease out ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... Ebola while working for NBC News in Liberia has ... isolation unit at Nebraska Medical Center in Omaha, where he had ... A blood test confirmed by the U.S. Centers for Disease ... to Providence, R.I., NBC News reported Tuesday night. ...
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... Omission leaves them without treatment for blood-borne diseases, researchers ... medical students get stuck by needles, putting them at ... alert hospital authorities, which increases their risk of infection, ... 699 surgery residents at 17 medical centers and found ...
... study, athletes had ,younger, immune cells than sedentary, healthy adults ... shown that exercise can help ward off heart disease and ... may be found within cells themselves. , , Endurance ... chromosomes that protect the cell -- in their white blood ...
... , LOS ANGELES, Nov. 30 ... woman, and brings with it a host of uncomfortable symptoms that ... weight gain , night sweats and lethargy are just some ... menopause signs and symptoms can show up a full ten ...
... , Sponsored by Merck, ... active participants in their HIV treatment decisions , ARLINGTON, ... the #1 HIV/AIDS resource online, today launched My Health Tracker, ... to save, track and analyze their medical data. The tool, ...
... ... A new poll released today by Latino Decisions, the ... New Mexico (UNM-RWJF Center), and impreMedia, shows a widespread consensus among the ... support for expansion of coverage. For the first time, health care tops ...
... , CHARLTON, Mass., Nov. 30 Harrington Physician ... Practice physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika ... esteemed and popular Charlton-based physicians, coming from the Fallon Clinic, ... HealthCare at Charlton medical office building under construction at 10 ...
Cached Medicine News:Health News:Med Students Often Fail to Report Needlestick Injuries 2Health News:Exercise Guards White Blood Cells Against Aging 2Health News:Exercise Guards White Blood Cells Against Aging 3Health News:Anti-Aging Institute of California Offers New Natural Solution for Menopause Symptoms 2Health News:TheBody.com Launches My Health Tracker, Enabling HIV-Positive Patients to Track Lab Results, Medications and Supplements 2Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 2Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 3Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 4Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 5Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 6Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 7Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 8Health News:New Survey Shows Overwhelming Support Among Latinos for Health Care Reform That Includes Public Option 9Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 3
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid NH, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: